LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
$2,38
Harga · Agu 18, 2026
Fundamental per Agu 6, 2026
Rentang 52M
$1–$3
82% of range
Peringkat Analis
BUY
11 analysts
Target Harga
$4
+62% upside
P/E (TTM)
-17.0
ROE
-39.7%
Margin Laba Bersih
-101.1%
Tentang Lexicon Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Baca selengkapnya
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
LXRX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$2.38
Kapitalisasi Pasar
$869M
P/E (TTM)
-17.0
EPS (TTM)
$-0.14
Pendapatan (TTM)
$50M
Imbal Hasil Dividen
—
ROE
-39.7%
D/E Utang/Ekuitas
0.5
Rentang 52M
$1 – $3
LXRX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$50M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
Arus Kas Bebas
$-68M
2016-12-31
→
2025-12-31
Margin
-101.1%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
LXRX
Median Rekan
P/E (TTM)
-17.0
29.9
P/S (TTM)
17.4
14.4
P/B
8.1
4.4
EV / EBITDA
-17.1
—
Price / FCF (Harga / FCF)
-12.8
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
LXRX
Median Rekan
Operating Margin (Margin Operasi)
-98.2%
—
Net Profit Margin (Margin Laba Bersih)
-101.1%
0.70%
ROA
-20.8%
-0.55%
ROE
-39.7%
-2.5%
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
LXRX
Median Rekan
Debt / Equity (Utang / Ekuitas)
0.5
—
Current Ratio (Rasio Lancar)
4.9
3.9
Quick Ratio (Rasio Cepat)
4.7
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
LXRX
Median Rekan
Revenue YoY (Pendapatan YoY)
60.2%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
610.2%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
15.7%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
LXRX
Median Rekan
LXRX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
11 analis
- Beli Kuat 3 27,3%
- Beli 5 45,5%
- Tahan 3 27,3%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
5 analis · 2026-08-19
Median
$3.10
Rata-rata
$3.86
Sekarang
$2.38
Rendah
$2.00
Tinggi
$6.00
Target median
$3.10
+30,5%
Target rata-rata
$3.86
+62,4%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.03%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.07 | $-0.05 | -0.02% |
| 31 Maret 2026 | $0.00 | $-0.04 | 0.04% |
| 31 Des. 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 Sep. 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 Juni 2025 | $0.01 | $-0.08 | 0.09% |
| 31 Maret 2025 | $-0.07 | $-0.10 | 0.03% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
| EYPT | $1.51B | -5.8 | -27.5% | -739.4% | -84.0% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | — |
| SGP | — | — | — | — | 50.0% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Neraca 30
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Arus Kas 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | -725,713,000 | 363,399,000 | 363,294,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | -307,937,000 | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | -725,989,000 | 363,399,000 | 363,570,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | 7,749,000 | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | $-26M | · | $-64M | $-55M | $-45M | · | $-50M | $-44M | $-31M | · | $-23M |
Neraca 28
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | $101M | · | $100M | $99M | $100M | · | $99M | $99M | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Arus Kas 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | $-22M | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Profitabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | -2034.8% | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | -13955.8% | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | -2004.4% | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | -14165.3% | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | -2020.8% | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | -13955.8% | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | -7.1% | · | -21.7% | -15.5% | -16.7% | · | -21.6% | -20.9% | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | -12.3% | · | -40.8% | -25.1% | -25.7% | · | -35.6% | -34.9% | -35.3% | · | -16.7% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | 2.2 | · | 7.5 | 11.5 | 15.6 | · | 6.9 | 10.1 | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | 2.2 | · | 7.2 | 11.2 | 15.3 | · | 6.8 | 9.9 | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.8 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | -22.6 | -17.1 | · | -26.7 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | 0.4 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | 0.1 | · | 1.1 | 1.0 | 1.3 | · | 0.9 | 0.9 | · | · | · |
Valuasi (TTM) 12
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65M | $65M | · | $46M | $34M | $6M | · | $5M | $3M | $2M | · | $542.0K | $415.0K | · | · | · | |
| Net Income TTM | $-42M | $-36M | · | $-100M | $-140M | $-192M | · | $-217M | $-197M | $-176M | · | $-151M | $-125M | $-103M | · | $-95M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -24.0 | -15.6 | · | -4.8 | -2.3 | -0.7 | · | -2.1 | -2.1 | -3.0 | · | -1.5 | · | · | · | · | |
| P/S | 16.5 | 10.2 | · | 10.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -35.2 | -613.0 | · | -35.6 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 14.4 | 8.3 | · | 9.4 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.2% | -6.4% | · | -20.7% | -43.2% | -134.8% | · | -48.4% | -47.6% | -33.3% | · | -67.0% | · | · | · | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $50M | $31M | $1M | $139.0K | $298.0K |
| Margin Operasi % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Laba Bersih | $-50M | $-200M | $-177M | $-102M | $-88M |
| EPS Dilusian | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.5 | 0.7 | 1.1 | — | 0.0 |
| Rasio Lancar | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Rasio Cepat | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-68M | $-180M | $-162M | $-90M | $-88M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 169 pengaju · $760.9M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 48 (+19 vs Kuartal sebelumnya) | 26 (+13 vs Kuartal sebelumnya) | 34 (-11 vs Kuartal sebelumnya) | 37 (+17 vs Kuartal sebelumnya) | +36.5M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| Artal Group S.A. | $420.374.549 | 175.156.062 | 55,25% | Saham |
| Siren, L.L.C. | $106.328.443 | 44.303.518 | 13,97% | Saham |
| FMR LLC | $65.057.059 | 27.107.108 | 8,55% | Saham |
| Sessa Capital IM, L.P. | $45.506.006 | 18.960.836 | 5,98% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.762.899 | 9.901.208 | 3,12% | Saham |
| Point72 Asset Management, L.P. | $19.803.180 | 8.251.325 | 2,60% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $12.946.507 | 5.393.025 | 1,70% | Saham |
| STATE STREET CORP | $11.802.646 | 4.917.769 | 1,55% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5.658.598 | 2.357.749 | 0,74% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.696.260 | 1.956.775 | 0,62% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $3.922.970 | 1.634.571 | 0,52% | Saham |
| CIBC Private Wealth Group LLC | $3.240.347 | 2.400.257 | 0,43% | Saham |
| Ishara Investments LP | $3.050.400 | 1.271.000 | 0,40% | Saham |
| MILLENNIUM MANAGEMENT LLC | $2.722.150 | 1.134.229 | 0,36% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $2.704.800 | 1.127.000 | 0,36% | Saham |
| MACKENZIE FINANCIAL CORP | $2.312.050 | 963.354 | 0,30% | Saham |
| ADAR1 Capital Management, LLC | $1.800.000 | 750.000 | 0,24% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.604.400 | 668.500 | 0,21% | Opsi beli |
| TWO SIGMA INVESTMENTS, LP | $1.544.266 | 643.444 | 0,20% | Saham |
| JANE STREET GROUP, LLC | $1.398.960 | 582.900 | 0,18% | Opsi beli |
| CITADEL ADVISORS LLC | $1.348.733 | 561.972 | 0,18% | Saham |
| VANGUARD GROUP INC | $1.277.587 | 1.110.945 | 0,17% | Saham |
| Compagnie Lombard Odier SCmA | $1.152.000 | 480.000 | 0,15% | Saham |
| BARCLAYS PLC | $890.636 | 371.098 | 0,12% | Saham |
| CITADEL ADVISORS LLC | $886.320 | 369.300 | 0,12% | Opsi beli |
| XTX Topco Ltd | $858.905 | 357.877 | 0,11% | Saham |
| GOLDMAN SACHS GROUP INC | $725.810 | 302.421 | 0,10% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $618.960 | 257.900 | 0,08% | Saham |
| RHUMBLINE ADVISERS | $616.523 | 256.885 | 0,08% | Saham |
| WELLS FARGO & COMPANY/MN | $544.865 | 227.027 | 0,07% | Saham |
| GROUP ONE TRADING LLC | $420.031 | 175.013 | 0,06% | Saham |
| Virtus Investment Advisers, LLC | $408.996 | 170.415 | 0,05% | Saham |
| Headlands Technologies LLC | $401.275 | 167.198 | 0,05% | Saham |
| Ikarian Capital, LLC | $395.218 | 164.674 | 0,05% | Saham |
| CITIGROUP INC | $386.021 | 160.842 | 0,05% | Saham |
| Quarry LP | $374.846 | 156.186 | 0,05% | Saham |
| MetLife Investment Management, LLC | $351.384 | 146.410 | 0,05% | Saham |
| Bank of New York Mellon Corp | $345.307 | 143.878 | 0,05% | Saham |
| BANK OF AMERICA CORP /DE/ | $344.321 | 143.467 | 0,05% | Saham |
| PANAGORA ASSET MANAGEMENT INC | $316.901 | 132.042 | 0,04% | Saham |
| State of Wyoming | $285.816 | 119.090 | 0,04% | Saham |
| BlackRock, Inc. | $284.436 | 118.515 | 0,04% | Saham |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $273.874 | 114.114 | 0,04% | Saham |
| Cornerstone Investment Partners, LLC | $272.974 | 113.739 | 0,04% | Saham |
| Invesco Ltd. | $238.190 | 99.246 | 0,03% | Saham |
| ALGERT GLOBAL LLC | $221.160 | 92.150 | 0,03% | Saham |
| TWO SIGMA ADVISERS, LP | $208.124 | 180.977 | 0,03% | Saham |
| BANK OF NOVA SCOTIA | $207.857 | 86.607 | 0,03% | Saham |
| LPL Financial LLC | $203.799 | 84.916 | 0,03% | Saham |
| Vanguard Global Advisers, LLC | $187.070 | 77.946 | 0,02% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $180.101 | 75.042 | 0,02% | Saham |
| Police & Firemen's Retirement System of New Jersey | $176.165 | 73.402 | 0,02% | Saham |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | $171.426 | 71.427 | 0,02% | Saham |
| PRUDENTIAL FINANCIAL INC | $171.228 | 71.345 | 0,02% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $167.393 | 69.747 | 0,02% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $164.160 | 68.400 | 0,02% | Saham |
| TWO SIGMA SECURITIES, LLC | $159.300 | 66.375 | 0,02% | Saham |
| SEI INVESTMENTS CO | $153.449 | 63.937 | 0,02% | Saham |
| Nuveen, LLC | $153.449 | 63.937 | 0,02% | Saham |
| Straight Path Wealth Management | $150.398 | 62.666 | 0,02% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $144.000 | 60.000 | 0,02% | Saham |
| R Squared Ltd | $131.964 | 54.985 | 0,02% | Saham |
| Vanguard Personalized Indexing Management, LLC | $130.402 | 54.334 | 0,02% | Saham |
| Fortis Group Advisors, LLC | $120.000 | 50.000 | 0,02% | Saham |
| Schonfeld Strategic Advisors LLC | $118.642 | 49.435 | 0,02% | Saham |
| SCOTIA CAPITAL INC. | $117.291 | 48.871 | 0,02% | Saham |
| PROFUND ADVISORS LLC | $116.606 | 48.586 | 0,02% | Saham |
| VOYA INVESTMENT MANAGEMENT LLC | $114.650 | 47.771 | 0,02% | Saham |
| AXQ CAPITAL, LP | $109.745 | 45.727 | 0,01% | Saham |
| BOOTHBAY FUND MANAGEMENT, LLC | $106.356 | 44.315 | 0,01% | Saham |
| ALLIANCEBERNSTEIN L.P. | $105.768 | 67.800 | 0,01% | Saham |
| WINTON GROUP Ltd | $103.680 | 43.200 | 0,01% | Saham |
| INTECH INVESTMENT MANAGEMENT LLC | $101.978 | 42.491 | 0,01% | Saham |
| LMR Partners LLP | $98.618 | 41.091 | 0,01% | Saham |
| BANK OF MONTREAL /CAN/ | $96.000 | 40.000 | 0,01% | Saham |
| NORTHERN TRUST CORP | $93.794 | 39.081 | 0,01% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $90.672 | 37.780 | 0,01% | Saham |
| Cubist Systematic Strategies, LLC | $85.704 | 63.484 | 0,01% | Saham |
| Rafferty Asset Management, LLC | $81.816 | 34.090 | 0,01% | Saham |
| ProShare Advisors LLC | $78.212 | 32.588 | 0,01% | Saham |
| Leonteq Securities AG | $72.000 | 30.000 | 0,01% | Saham |
| PINNACLE ASSOCIATES LTD | $69.636 | 29.015 | 0,01% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $58.135 | 24.223 | 0,01% | Saham |
| Legal & General Group Plc | $58.044 | 24.185 | 0,01% | Saham |
| XPONANCE LLC | $57.031 | 23.763 | 0,01% | Saham |
| Graham Capital Management, L.P. | $56.498 | 23.541 | 0,01% | Saham |
| D. E. Shaw & Co., Inc. | $53.280 | 22.200 | 0,01% | Saham |
| Quadrature Capital Ltd | $52.795 | 21.998 | 0,01% | Saham |
| Invera Wealth Advisors, LLC | $48.000 | 20.000 | 0,01% | Saham |
| DIKER MANAGEMENT LLC | $48.000 | 20.000 | 0,01% | Saham |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | $48.000 | 20.000 | 0,01% | Saham |
| Russell Investments Group, Ltd. | $47.764 | 19.902 | 0,01% | Saham |
| Point72 Asia (Singapore) Pte. Ltd. | $47.282 | 35.024 | 0,01% | Saham |
| Tower Research Capital LLC (TRC) | $46.764 | 19.485 | 0,01% | Saham |
| KWB Wealth | $46.736 | 40.640 | 0,01% | Saham |
| SBI Securities Co., Ltd. | $46.092 | 19.205 | 0,01% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $45.682 | 19.034 | 0,01% | Saham |
| CREDIT AGRICOLE S A | $45.540 | 18.975 | 0,01% | Saham |
| WOLVERINE TRADING, LLC | $43.785 | 31.500 | 0,01% | Opsi jual |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $42.960 | 17.900 | 0,01% | Opsi jual |
Orang dalam perusahaan 49 orang dalam · 32 pejabat · 19 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 Feb. 2026 M | 298.432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 Feb. 2024 M | 1.098.068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 Feb. 2014 M | 1.021.329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 Feb. 2026 M | 105.356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 Juni 2009 A | — | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 Feb. 2008 A | 50.200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 Juli 2024 A | 324.214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 Feb. 2026 M | 31.264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 Feb. 2026 M | 150.132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 Feb. 2026 M | 277.945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 Feb. 2026 M | 323.430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 Feb. 2026 M | 93.869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 Feb. 2026 M | 428.802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 Feb. 2025 M | 76.368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 Feb. 2025 M | 339.104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 Feb. 2025 A | — | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 Feb. 2024 M | 162.672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 Feb. 2024 A | — | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 Feb. 2023 M | 53.136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 Maret 2021 M | 71.766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 April 2020 F | 55.584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 April 2020 F | 85.719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 Maret 2015 M | 8.235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 Feb. 2014 M | 278.703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 Feb. 2010 A | — | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 Feb. 2010 A | 27.306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 Feb. 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 Feb. 2008 A | 10.200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 Feb. 2008 A | — | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 Feb. 2007 A | — | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 Feb. 2004 M | 15.000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 Jan. 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Direktur | 3 Juni 2026 M | 89.312 | 0 | 0 | $0 |
| Diane E. Sullivan | Direktur | 3 Juni 2026 M | 126.122 | 0 | 0 | $0 |
| Judith L Swain | Direktur | 3 Juni 2026 M | 174.486 | 0 | 0 | $0 |
| Amouyal Philippe | Direktur | 3 Juni 2026 M | 374.486 | 0 | 0 | $0 |
| Sam L Barker | Direktur | 3 Juni 2026 M | 213.771 | 0 | 0 | $0 |
| Christopher J Sobecki | Direktur | 3 Juni 2026 M | 293.177 | 0 | 0 | $0 |
| Raymond Debbane | Direktur | 3 Juni 2026 M | 1.995.498 | 7 | 0 | $723.048 |
| Robert J Lefkowitz MD | Direktur | 13 Mei 2024 A | 48.364 | 0 | 0 | $0 |
| Frank Palantoni | Direktur | 21 Mei 2023 M | 40.332 | 0 | 0 | $0 |
| Alan S Nies | Direktur | 21 Mei 2023 M | 41.046 | 0 | 0 | $0 |
| Invus C.V. | Direktur | 31 Des. 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Direktur | 24 April 2009 A | — | 0 | 0 | $0 |
| Clayton Stuart Rose | Direktur | 26 Juni 2007 P | 25.000 | 0 | 0 | $0 |
| Barry Mills | Direktur | 26 April 2007 A | 25.000 | 0 | 0 | $0 |
| Patricia M Cloherty | Direktur | 27 April 2006 A | — | 0 | 0 | $0 |
| Thomas C Caskey | Direktur | 13 Okt. 2005 P | 6.300 | 0 | 0 | $0 |
| Praveen Tyle | — | 28 Feb. 2021 M | 120.791 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 11 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 pengajuan | 8 Mei 2026 | 39,40% | Amandemen | — | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 pengajuan | 9 Des. 2024 | — | Pengajuan awal | — | SEC |
| 24 Feb. 2012 | — | Pengajuan awal | — | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 Des. 2011 | — | Pengajuan awal | — | SEC |
| 14 Nov. 2011 | — | Pengajuan awal | — | SEC | |
| 15 Agu 2011 | — | Pengajuan awal | — | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 Maret 2010 | — | Pengajuan awal | — | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 pengajuan | 5 Agu 2005 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 8 Agu 2003 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 18 Juli 2003 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 19 Maret 2003 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 14 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,56% | 51.356 SH | 8 Agu 2026 | Harian |
| IWC · iShares Trust | 0,13% | 841.693 SH | 8 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 266.401 SH | 8 Agu 2026 | Harian |
| IWO · iShares Trust | 0,04% | 2.223.001 SH | 8 Agu 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 323.271 SH | 8 Agu 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1.432.882 SH | 8 Agu 2026 | Harian |
| IWM · iShares Trust | 0,02% | 6.194.737 SH | 8 Agu 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2.594.934 SH | 8 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 637.561 SH | 8 Agu 2026 | Harian |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 1.032.223 NS | 31 Mei 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 84.479 SH | 8 Agu 2026 | Harian |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 110.085 NS | 31 Mei 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7.083.651 SH | 8 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20.905 SH | 8 Agu 2026 | Harian |